Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...

Regeneron and Sanofi’s Dupixent trial shows major improvement in allergic fungal rhinosinusitis symptoms in patients 6+. Read ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

S anofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and ...

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Nektar Therapeutics has pivoted from oncology to focus on autoimmune and inflammatory diseases. Read why I rate NKTR stock a ...

Most patients with chronic rhinosinusitis with nasal polyps no longer used oral corticosteroids after using dupilumab, according to data presented at the American College of Allergy, Asthma & ...

Pfizer seals the deal with Metsera for $10 billion after Novo Nordisk bowed out; President Donald Trump welcomes executives ...

Sanofi’s stock narrative is shifting as analysts revise their consensus price target slightly downward, from $106.90 to $106.85. This minor adjustment reflects a careful reassessment of Sanofi’s ...